CJC-1295 Ipamorelin: The Clinician’s Guide to the GH Stack

August 11, 2026
Hands drawing peptide injection from vial

The CJC-1295 ipamorelin stack pairs a growth hormone-releasing hormone (GHRH) analog with a selective ghrelin-receptor agonist to amplify your body’s own GH pulses rather than replace them. Used together, they hit two separate receptor pathways simultaneously, producing a stronger GH release than either peptide can achieve alone. Most clinician-supervised protocols start at 100–200 mcg of each per injection, dosed once nightly or up to twice daily, in cycles of 8–12 weeks.

The single most important safety caveat before you start: get baseline labs first. IGF-1 and fasting glucose are the minimum. Elevated IGF-1 or impaired glucose handling can worsen under GH stimulation, and neither issue announces itself with symptoms you’d notice in week one.

Quick verdict:

  • What it does: Amplifies natural GH pulses via two complementary pathways for body composition, recovery, and sleep quality improvements.
  • Standard dose range: 100–200 mcg of each peptide per injection; 1–2x daily, typically at bedtime.
  • Cycle length: 8–12 weeks on, 4–8 weeks off is the most common clinician-supervised template.
  • Non-negotiable: Baseline IGF-1, fasting glucose, and a licensed clinician’s sign-off before starting.

Talk to a licensed clinician before ordering anything. The peptides themselves are only part of the equation; the protocol around them is what separates a safe, effective course from an expensive gamble.

Key Takeaways

The CJC-1295 ipamorelin stack produces its strongest results when the no-DAC (Mod GRF 1-29) variant is paired with ipamorelin, dosed nightly in a fasted state, and monitored with baseline and follow-up IGF-1 and glucose labs under clinician supervision.

Point Details
Use no-DAC CJC for pulsatile stacks Mod GRF 1-29 (no DAC) preserves physiological GH pulse architecture; DAC’s 5.8–8.1 day half-life is not suited to pulsatile protocols.
Baseline labs are required IGF-1, fasting glucose, HbA1c, and a CMP before starting; repeat IGF-1 at weeks 4–8 to guide dose adjustments.
Dose range and cycle length Standard protocols use 100–200 mcg of each peptide per injection, once nightly or twice daily, in 8–12 week cycles.
Evidence supports biomarkers, not outcomes Component-level trials confirm GH and IGF-1 elevation; no RCT has validated the combined no-DAC CJC + ipamorelin protocol for fat loss or muscle gain.
Revive Meds provides supervised access Clinician intake, purity-tested compounding, and ongoing provider messaging for the full cycle, with no membership fees.

Table of Contents

What CJC-1295 and ipamorelin actually are

These are not interchangeable names for the same thing. Three distinct molecules get grouped under the “CJC-1295 ipamorelin” label, and knowing which is which changes everything about how you dose.

CJC-1295 with DAC (Drug Affinity Complex) binds albumin in the bloodstream, which dramatically extends its half-life to roughly 5.8–8.1 days. That long duration keeps GH and IGF-1 elevated continuously rather than in pulses. Clinically useful for some applications, but it blunts the pulsatile GH architecture that most longevity and body-composition protocols are trying to preserve.

CJC-1295 without DAC (also called Mod GRF 1-29) has a short half-life of roughly 30 minutes. It loads the pituitary’s somatotroph cells with GH-releasing signal, then clears quickly. This is the version used in the standard pulse stack with ipamorelin, and it’s the one this guide focuses on.

Ipamorelin is a selective ghrelin-receptor agonist (GHS-R1a). It triggers GH release without the cortisol and prolactin spikes that older growth hormone-releasing peptides (GHRPs) like GHRP-6 produce. That selectivity is the main reason ipamorelin became the preferred pairing for CJC-1295 no-DAC.

Pro Tip: Check your vial label carefully. If it says “CJC-1295” with no further qualifier, ask the compounding pharmacy whether it contains DAC. The dosing schedule is a clue too: a once-weekly injection suggests DAC; a nightly injection suggests no-DAC (Mod GRF 1-29).

How CJC-1295 and ipamorelin work together

The synergy here is mechanistic, not just additive. GHRH analogs like CJC-1295 no-DAC act on the pituitary’s somatotroph cells to increase the GH pool available for release. Ipamorelin, working through the ghrelin receptor, then triggers that release. One peptide fills the tank; the other pulls the trigger.

Neither pathway alone produces the same peak GH response as both together. Research on GH secretagogue pharmacology consistently shows that GHRH analogs and ghrelin-pathway agonists act on distinct receptors and produce synergistic rather than simply additive GH output.

Why pulsatility matters:

  • Natural GH is released in pulses, primarily during deep sleep. Continuous elevation (as with DAC) can desensitize receptors over time.
  • The no-DAC CJC + ipamorelin combination preserves that pulse architecture because both peptides clear within 1–2 hours.
  • Physiological GH pulses drive the downstream IGF-1 response that supports tissue repair, fat metabolism, and lean mass retention.

Timing implications: Dosing 2–3 hours after your last meal, just before sleep, aligns the induced GH pulse with the body’s natural nocturnal GH surge. Elevated insulin from a recent meal blunts GH release, so the fasting window is not optional. A pre-workout dose is a secondary option some protocols use, but the bedtime dose remains the anchor.

What the evidence actually supports for CJC-1295 ipamorelin benefits

The claimed benefits of this stack range from well-supported to speculative. Here’s where the evidence sits for each major category.

Claimed Benefit Mechanistic Plausibility Strength of Human Evidence
Increased IGF-1 / GH biomarkers High (direct pharmacology) Moderate (component-level trials)
Improved sleep quality Moderate (GH pulse timing) Limited (indirect/self-reported)
Faster recovery / reduced soreness Moderate (GH-driven protein synthesis) Limited (no RCT for this stack)
Reduced body fat Moderate (GH lipolytic effects) Limited (no RCT for this stack)
Lean muscle support Moderate (IGF-1 anabolic signaling) Limited (no RCT for this stack)
Anti-aging / longevity Low-to-moderate (GH axis decline with age) Very limited (no long-term data)

Comparison chart of CJC-1295 ipamorelin benefits and evidence

The honest framing: clinical data supports each component’s ability to raise GH or IGF-1 biomarkers. What those biomarker changes translate to in terms of fat loss, muscle gain, or longevity in healthy adults is less clear. A 2023 Frontiers in Endocrinology review underscores that while mechanistic rationale for GH secretagogues is solid, randomized controlled trial data for specific stacked protocols in healthy adults remains sparse.

The Mayo Clinic’s overview of growth hormone notes that GH’s metabolic effects on body composition are real but context-dependent: diet, training, sleep, and baseline hormonal status all modulate outcomes significantly.

Key clinical studies and what they actually found

The most cited human trial for this class of compounds is Teichman et al. (2006), a Phase 1 study of CJC-1295 with DAC in healthy adults. It showed dose-dependent GH increases of 2–10-fold lasting six or more days, and IGF-1 elevations of 1.5–3-fold sustained for 9–11 days. After multiple doses, IGF-1 elevations persisted for up to 28 days. These are meaningful pharmacokinetic signals, but the study was a Phase 1 safety and PK trial, not a body-composition or longevity outcome study.

For ipamorelin specifically, foundational pharmacology work established its selectivity for GH release over cortisol and prolactin, a profile that sets it apart from earlier GHRPs. Human PK/PD characterization supports its use as a “clean” secretagogue, though large-scale outcome trials in healthy adults are not available.

Trial / Source Population Primary Outcomes Key Findings
Teichman et al. 2006 (Phase 1) Healthy adults GH and IGF-1 PK/PD GH 2–10x increase ≥6 days; IGF-1 1.5–3x; DAC half-life 5.8–8.1 days
Ipamorelin PK studies (Raun et al.) Preclinical / early human PK GH selectivity, cortisol/prolactin Selective GH release; minimal cortisol/prolactin elevation
Frontiers in Endocrinology 2023 Review (GH secretagogues) Evidence gaps, mechanisms No RCT for no-DAC CJC + ipamorelin combination in healthy adults

The gap worth noting: no randomized controlled trial has tested the specific CJC-1295 no-DAC + ipamorelin combination in healthy adults. The PubMed literature on this stack is largely component-level. Protocols in clinical practice are built on mechanistic rationale and component-level data, not a dedicated combination trial.

CJC-1295 dosing and administration: practical templates

These templates reflect clinician-supervised starting points. Individual adjustments based on IGF-1 response and tolerance are expected.

Conservative (starting) protocol:

  • CJC-1295 no-DAC: 100 mcg per injection
  • Ipamorelin: 100 mcg per injection
  • Frequency: once nightly, 30 minutes before sleep
  • Cycle: 8 weeks on, 4 weeks off

Standard protocol:

  • CJC-1295 no-DAC: 200 mcg per injection
  • Ipamorelin: 200 mcg per injection
  • Frequency: once nightly or twice daily (morning fasted + bedtime)
  • Cycle: 10–12 weeks on, 4–8 weeks off

Higher-dose protocol (clinician-supervised only):

  • 300 mcg of each per injection
  • Reserved for patients with confirmed low IGF-1 at baseline and documented tolerance at lower doses

Injection and handling checklist:

  • Use a 27–31 gauge, 0.5-inch insulin syringe for subcutaneous injection.
  • Preferred sites: abdomen (2 inches from navel), outer thigh, or upper arm.
  • Both peptides can be drawn into the same syringe if reconstituted separately first.
  • Reconstitute with bacteriostatic water; add diluent slowly down the vial wall, do not shake.
  • Store reconstituted vials refrigerated at 36–46°F; use within 28–30 days.
  • Inject 2–3 hours after your last meal to avoid insulin-driven GH suppression.

Pro Tip: Rotate injection sites with each dose. Repeated injections at the same spot can cause localized lipodystrophy over a multi-week cycle.

Never adjust dose upward without a follow-up IGF-1 lab. The number on the vial is a starting point, not a target.

Side effects, contraindications, and the monitoring plan

Side effects, contraindications, and the monitoring plan — overview diagram

CJC-1295 ipamorelin side effects range from mild and expected to rare but serious. Knowing the difference matters.

Common and expected:

  • Water retention (especially in the first 2–4 weeks)
  • Transient tingling or numbness in hands/feet (paresthesia)
  • Increased appetite
  • Mild injection-site redness or irritation
  • Vivid dreams or changes in sleep architecture

Less common but clinically significant:

  • Glucose dysregulation: GH is counter-regulatory to insulin. The Cleveland Clinic’s clinical overview notes that elevated GH can impair glucose handling, which is especially relevant for anyone with prediabetes or insulin resistance.
  • Systemic vasodilation and transient hypotension
  • Cardiovascular stress at higher doses

The FDA’s compounding guidance flags certain compounded peptides for potential safety risks including impurity-related adverse events and cardiovascular concerns, which reinforces why sourcing from verified, purity-tested pharmacies matters as much as the protocol itself.

Absolute contraindications:

  • Active cancer or personal history of hormone-sensitive cancer
  • Uncontrolled diabetes or HbA1c above 8%
  • Active cardiovascular disease or recent cardiac event
  • Pregnancy or breastfeeding
  • Pituitary disease or known pituitary tumor
  • Pediatric patients (under 18)

Monitoring checklist:

  • Baseline (before first dose): IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel (CMP), lipid panel.
  • Week 4–8: Repeat IGF-1 and fasting glucose; assess for water retention and paresthesia.
  • Week 12 (end of cycle): Full metabolic panel, IGF-1, and clinical review before deciding on a second cycle.

Red flags — stop and seek care immediately:

  • Palpitations or chest tightness
  • Syncope or near-syncope
  • Rapid unexplained swelling beyond mild water retention
  • Fasting glucose above 126 mg/dL on repeat testing
  • New neurologic symptoms (vision changes, severe headache)

Pro Tip: Keep a simple symptom log during the first cycle. Water retention and paresthesia typically resolve within 2–4 weeks; if they don’t, that’s a signal to contact your clinician before the scheduled check-in.

What to expect and when: a realistic timeline

Results from the CJC-1295 ipamorelin stack do not appear on a uniform schedule. Biomarker changes come first; clinical outcomes take longer.

  1. Weeks 1–2: Some patients notice improved sleep depth and more vivid dreams within the first week. Appetite may increase. Water retention often peaks here.
  2. Weeks 2–4: Energy and recovery subjectively improve for many patients. These are the earliest clinical signals worth tracking.
  3. Weeks 4–8: IGF-1 shifts become measurable on labs. This is the first checkpoint where dose adjustments are evidence-based rather than guesswork.
  4. Weeks 8–12: Body-composition changes (reduced fat, improved lean mass) become visible when combined with consistent training and adequate protein intake. These changes are modest without lifestyle support.
  5. Month 3 comprehensive review: Full metabolic panel, IGF-1, clinical assessment, and a decision on whether to continue, adjust, or cycle off.

What to track weekly: sleep quality (subjective 1–10 scale), morning weight, appetite changes, and any side effects. Body-composition measurements (waist circumference, body fat percentage if available) every 4 weeks give more signal than daily weight fluctuations.

Peptides like CJC-1295 and ipamorelin are not FDA-approved drugs for general use. In the U.S., they are available only through a licensed prescriber, typically supplied as compounded products from a registered compounding pharmacy. The FDA’s bulk drug substance guidance identifies certain compounded peptides as carrying potential safety risks, which is why the regulatory framework requires a prescription and clinician oversight.

For a deeper look at the current regulatory picture, Revive Meds has a detailed breakdown of FDA peptide approvals and restrictions that’s worth reading before you start. A broader overview of peptide legality in the U.S. covers the nuances that most generic guides miss.

Safe procurement steps:

  1. Get a prescription from a licensed clinician who has reviewed your labs and medical history.
  2. Use only FDA-registered compounding pharmacies with documented purity testing (99%+ is the standard to ask for).
  3. Confirm cold-chain shipping: peptides degrade at room temperature, and a pharmacy that ships without refrigeration is a red flag.
  4. Request a certificate of analysis (COA) for your specific batch.

Red flags for unsafe sources:

  • No prescription required
  • No third-party purity testing or COA available
  • Overseas supplier with no traceable U.S. compounding license
  • Claims of guaranteed clinical outcomes

Questions to ask your telehealth provider before ordering:

  • Are you a licensed prescriber in my state?
  • Which compounding pharmacy do you use, and is it FDA-registered?
  • Do you provide a COA for each batch?
  • What labs do you require before prescribing?
  • How do you monitor patients during a cycle?

Pro Tip: A telehealth provider who skips baseline labs or doesn’t ask about your medical history before prescribing is not following a safe protocol. That’s the single fastest way to screen out low-quality services.

How to transition off CJC-1295 ipamorelin without a rebound

Stopping abruptly after a full cycle is generally well-tolerated because these peptides stimulate your own GH production rather than replacing it. That said, a structured taper reduces the chance of a subjective “crash” in energy or sleep quality.

A standard off-ramp over 2 weeks: reduce injection frequency from twice daily to once daily in week one, then to every other day in week two, then stop. If you were on a once-nightly protocol, simply stopping at the end of the cycle is typically fine, but some clinicians prefer a 1-week half-dose taper.

During the off-cycle period (typically 4–8 weeks), your pituitary’s natural GH pulsatility resumes. IGF-1 will drift back toward your baseline over 2–4 weeks. Maintaining training intensity and protein intake during this window helps preserve the body-composition gains made during the cycle. A follow-up IGF-1 lab 4 weeks after stopping confirms your axis has returned to baseline before starting a second cycle.

Hormonal imbalances from this stack are uncommon when protocols are clinician-supervised, but anyone with symptoms of persistent fatigue, libido changes, or mood disruption after stopping should get a full hormonal panel rather than assuming it will self-resolve.

Lifestyle factors that make or break your results

The peptide stack amplifies what you’re already doing. It does not replace the inputs that drive GH-axis health.

Nutrition: GH is strongly lipolytic, meaning it mobilizes fat for fuel. A diet with adequate protein (0.7–1.0 g per pound of body weight) and controlled carbohydrate intake in the evening maximizes the fat-mobilizing effect of the nocturnal GH pulse. Eating a large carbohydrate meal right before your bedtime injection blunts GH release via insulin elevation.

Exercise: Resistance training is the most potent natural GH stimulus outside of sleep. Compound movements (squats, deadlifts, rows) performed 3–5 days per week create the anabolic environment where elevated IGF-1 has the most to work with. High-intensity interval training (HIIT) adds a secondary GH pulse that can stack with the peptide-induced one.

Sleep hygiene: The majority of natural GH secretion happens during slow-wave (deep) sleep, typically in the first 90 minutes after sleep onset. Alcohol, blue light exposure within an hour of bed, and irregular sleep schedules all suppress slow-wave sleep and reduce the GH pulse the peptide stack is designed to amplify. Targeting 7–9 hours with consistent sleep and wake times is not optional if you want the protocol to perform.

Stress management: Chronically elevated cortisol suppresses GH release at the hypothalamic level. Practices that lower cortisol (consistent sleep, moderate training load, stress reduction) directly support the stack’s effectiveness. This is one reason the selective profile of ipamorelin matters: it avoids adding cortisol on top of what chronic stress already contributes.

Why clinician oversight changes the outcome

The difference between a well-run peptide protocol and a frustrating one usually comes down to the quality of the medical oversight, not the peptides themselves. Anyone can order a vial. What you can’t replicate without a clinician is the baseline lab interpretation, the dose calibration against your actual IGF-1 response, and the early identification of a contraindication that would have made the whole cycle unsafe.

Peptide therapy works best when it’s individualized. Two people at the same age and body weight can have meaningfully different IGF-1 baselines, different glucose handling, and different GH pulse patterns. A protocol built on those individual numbers performs better and carries less risk than a one-size template from a forum. Clinician-supervised care also means you have someone to call when the water retention in week two feels worse than expected, or when your sleep changes in a way that concerns you.

Revive Meds builds every peptide protocol around a full medical intake, baseline labs, and ongoing provider messaging. That structure is what makes the difference between a protocol that’s monitored and one that’s just hoped for.

Clinician-supervised peptide therapy at Revive Meds

If you’ve read this far, you understand that the CJC-1295 ipamorelin stack is not a supplement you self-prescribe. The protocol works. The evidence for the components is real. But the safety and the results both depend on doing it right.

Revive Meds

No membership fees. Unlimited provider messaging throughout your cycle so you’re never managing side effects or dose questions alone. HSA/FSA eligible, same-day onboarding.

Your first step is a medical intake, not a checkout cart. A clinician reviews your history and labs before anything is prescribed. To get started, visit Revive Meds and complete your intake today.

Sources

  • Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
  • Fda
  • Pmc
  • Mayoclinic
  • My
  • Frontiersin

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.